🇺🇸 FDA
Patent

US 11660330

Combination therapy with semaphorin-4D blockade (SEMA4D) and DC1 therapy

granted A61KA61K2035/122A61K2039/505

Quick answer

US patent 11660330 (Combination therapy with semaphorin-4D blockade (SEMA4D) and DC1 therapy) held by VACCINEX, INC. expires Mon May 25 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
VACCINEX, INC.
Grant date
Tue May 30 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 25 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
6
CPC classes
A61K, A61K2035/122, A61K2039/505, A61K2239/31, A61K2239/49